Table 2.

CAFs-associated inhibitors in ovarian cancer.

Inhibitors	Targets	Functions	Reference
Tocilizumab	IL-6R	Promotes anti-tumor immunity	[108]
INCB28060	HGF and c-Met	Blocks chemotherapeutic failure	[49]
PD173074	FGF	Terminates cellular proliferation and migration	[50]
Galunisertib	TGF-β1	Reverses MHC-I loss caused by TGF-β	[72]
DNMT	MHC-I	Inhibits tumor-immune excluded subtype	[52]
MPDL3280A	PD-L1	Suppresses T cell migration, proliferation, and secretion of cytotoxic mediators and restricts tumor cell killing	[109]
Vigil	TGFβ-1 and TGFβ-2	Downregulates TGF-β 1 and 2; provides personal neoantigen; induces GMCSF expression	[110]
AG1478	EGFR	Upregulates autophagy levels	[111]
Elaiophylin	Autophagy	Inhibits activation of autophagy	[112]
Bevacizumab	VEGF	Inhibits tumor angiogenesis	[99,113,114]

CAFs: cancer-associated fibroblasts.